VIRGINIA BEACH, VA --
The Board of Directors of The Gabelli Convertible and Income Securities
Fund Inc. (NYSE:GCV) (the “Fund”) reaffirmed its 8% distribution policy
and declared a $0.15 per share cash distribution payable on December 19,
2014 to common stock shareholders of record on December 12, 2014.
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer by the targeted killing of cancer stem cells,
today announced four poster presentations at the 26 th
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
taking place November 18 - 21, 2014, in Barcelona, Spain.
United Natural Foods, Inc. (Nasdaq: UNFI) (the "Company") announced
today that it will release its financial results for the first quarter
of fiscal 2015, ended November 1, 2014, before market open on Thursday,
December 4, 2014.
STORE Capital Corporation (NYSE: STOR), an internally managed net-lease
real estate investment trust (REIT) that invests in S ingle T enant
O perational R eal E state, today announced that it
has completed its initial public offering of 31,625,000 shares of its
common stock, including 4,125,000 shares of common stock sold in
connection with the full exercise of the underwriters’ option to
purchase additional shares, at a price to the public of $18.50 per
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating small
molecule drugs primarily in the infectious disease field, today
announced that Jay R.
Biomarker Studies Demonstrate On-Target Effects of Tarextumab Against Notch Pathway and Cancer Stem Cells in Patients With Pancreatic Cancer Patient-Derived Preclinical and Clinical Data Support the Phase 2 Development of Demcizumab With Abraxane and Gemcitabine in Pancreatic Cancer
BARCELONA, Spain and REDWOOD CITY, Calif., Nov.
a Sanofi company, announced today that the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency (EMA) has
adopted a positive opinion recommending approval of Cerdelga ®
(eliglustat) capsules, an oral treatment for certain adults living with
Gaucher disease type 1.
Sign-up for Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115 investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.